234 related articles for article (PubMed ID: 28209338)
1. The pharmacist role in the development and implementation of a naloxone prescription program in Alabama.
Wulz JL; Sung H; Dugan BD; Wensel TM; Lander R; Manzella B
J Am Pharm Assoc (2003); 2017; 57(2S):S141-S147. PubMed ID: 28209338
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
3. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
[TBL] [Abstract][Full Text] [Related]
4. Implementing take-home naloxone in an urban community pharmacy.
Akers JL; Hansen RN; Oftebro RD
J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
[TBL] [Abstract][Full Text] [Related]
5. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
Palmer E; Hart S; Freeman PR
J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
[TBL] [Abstract][Full Text] [Related]
6. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
[TBL] [Abstract][Full Text] [Related]
7. Strategies and policies to address the opioid epidemic: A case study of Ohio.
Penm J; MacKinnon NJ; Boone JM; Ciaccia A; McNamee C; Winstanley EL
J Am Pharm Assoc (2003); 2017; 57(2S):S148-S153. PubMed ID: 28189539
[TBL] [Abstract][Full Text] [Related]
8. Implementing an overdose education and naloxone distribution program in a health system.
Devries J; Rafie S; Polston G
J Am Pharm Assoc (2003); 2017; 57(2S):S154-S160. PubMed ID: 28233681
[TBL] [Abstract][Full Text] [Related]
9. State legal innovations to encourage naloxone dispensing.
Davis C; Carr D
J Am Pharm Assoc (2003); 2017; 57(2S):S180-S184. PubMed ID: 28073688
[TBL] [Abstract][Full Text] [Related]
10. The implementation of a naloxone rescue program in university students.
Panther SG; Bray BS; White JR
J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
[TBL] [Abstract][Full Text] [Related]
11. Naloxone for Opioid Overdose and the Role of the Pharmacist.
Toderika Y; Williams S
Consult Pharm; 2018 Feb; 33(2):98-104. PubMed ID: 29409576
[TBL] [Abstract][Full Text] [Related]
12. Development of a targeted naloxone coprescribing program in a primary care practice.
Wilson CG; Rodriguez F; Carrington AC; Fagan EB
J Am Pharm Assoc (2003); 2017; 57(2S):S130-S134. PubMed ID: 28189537
[TBL] [Abstract][Full Text] [Related]
13. The pharmacist's role in overdose: Using mapping technologies to analyze naloxone and pharmacy distribution.
Burrell A; Ethun L; Fawcett JA; Rickard-Aasen S; Williams K; Kearney SM; Pringle JL
J Am Pharm Assoc (2003); 2017; 57(2S):S73-S77.e1. PubMed ID: 28109629
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a pharmacist-led service for patients at high risk for opioid overdose.
Tewell R; Edgerton L; Kyle E
Am J Health Syst Pharm; 2018 Mar; 75(6):376-383. PubMed ID: 29523534
[TBL] [Abstract][Full Text] [Related]
15. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond.
Lenton S; Dietze P; Olsen A; Wiggins N; McDonald D; Fowlie C
Drug Alcohol Rev; 2015 Jul; 34(4):404-11. PubMed ID: 25272281
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
Cariveau D; Fay AE; Baker D; Fagan EB; Wilson CG
J Am Pharm Assoc (2003); 2019; 59(6):867-871. PubMed ID: 31466899
[TBL] [Abstract][Full Text] [Related]
17. Assessing the impact of clinical pharmacists on naloxone coprescribing in the primary care setting.
Watson A; Guay K; Ribis D
Am J Health Syst Pharm; 2020 Mar; 77(7):568-573. PubMed ID: 32207821
[TBL] [Abstract][Full Text] [Related]
18. Pharmacist-led health-system approaches to reduce opioid overdose and death.
Saldaña SN; Weaver N; Stanford B
J Am Pharm Assoc (2003); 2017; 57(2S):S8-S9. PubMed ID: 27865761
[No Abstract] [Full Text] [Related]
19. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
[TBL] [Abstract][Full Text] [Related]
20. Opioid education and nasal naloxone rescue kits in the emergency department.
Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
